Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Intravenous immunoglobulin and multiple sclerosis.

Literature DB >> 16391400

Intravenous immunoglobulin and multiple sclerosis.

Abstract

Intravenous immunoglobulin (IVIg) has been used as an immunomodulatory therapy for the treatment of multiple sclerosis (MS). In the current review, we summarize the up-to-date data related to IVIg clinical trials in MS, and the suggested mechanisms of action by which IVIg modulates the relevant immunological pathways impaired in MS.

Entities: Disease

Mesh：

Substances：

Year: 2005 PMID： 16391400 DOI： 10.1385/CRIAI:29:3:247

Source DB: PubMed Journal: Clin Rev Allergy Immunol ISSN： 1080-0549 Impact factor: 8.667

47 in total

Review 1. Immunomodulatory action of intravenous immunoglobulin.

Authors: W A C Sewell; S Jolles
Journal: Immunology Date: 2002-12 Impact factor: 7.397

2. Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin.

Authors: M Toyoda; X Zhang; A Petrosian; O A Galera; S J Wang; S C Jordan
Journal: J Clin Immunol Date: 1994-05 Impact factor: 8.317

3. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.

Authors: C Lucchinetti; W Brück; J Parisi; B Scheithauer; M Rodriguez; H Lassmann
Journal: Ann Neurol Date: 2000-06 Impact factor: 10.422

4. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg).

Authors: V Hurez; S V Kaveri; A Mouhoub; G Dietrich; J C Mani; D Klatzmann; M D Kazatchkine
Journal: Ther Immunol Date: 1994-10

Review 5. Pooled human IgG modulates cytokine production in lymphocytes and monocytes.

Authors: U Andersson; L Björk; U Skansén-Saphir; J Andersson
Journal: Immunol Rev Date: 1994-06 Impact factor: 12.988

Review 6. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy.

Authors: Y Abe; A Horiuchi; M Miyake; S Kimura
Journal: Immunol Rev Date: 1994-06 Impact factor: 12.988

1. Safety and effectiveness assessment of intravenous immunoglobulin in the treatment of relapsing-remitting multiple sclerosis: A meta-analysis.

Authors: Alireza Olyaeemanesh; Mahbobeh Rahmani; Reza Goudarzi; Abulghasem Rahimdel
Journal: Med J Islam Repub Iran Date: 2016-02-23

1 in total

Intravenous immunoglobulin and multiple sclerosis.

Review 1. Immunomodulatory action of intravenous immunoglobulin.

2. Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin.

3. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.

4. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg).

Review 5. Pooled human IgG modulates cytokine production in lymphocytes and monocytes.

Review 6. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy.

7. Antimyelin basic protein and antimyelin antibody-producing cells in multiple sclerosis.

Review 8. Antibody-mediated remyelination: relevance to multiple sclerosis.

9. IVIg therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment.

10. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial.

1. Safety and effectiveness assessment of intravenous immunoglobulin in the treatment of relapsing-remitting multiple sclerosis: A meta-analysis.